Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 11/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20986525 | 1.00 | PARP1 (0.55) | PARP1HTR2BHTR2CHTR2AMAPK1 | |
| Hydrochloric Acid SCHEMBL30321069 | 0.81 | ALDH1A1 (0.43) | PARP1ALDH1A1ADAM17 | |
| SCHEMBL20986449 | 0.80 | PARP1 (0.46) | PARP1HTR2BHTR2CHTR2AMAPK1 | |
| SCHEMBL20986452 | 0.80 | PARP1 (0.46) | PARP1HTR2BHTR2CHTR2AMAPK1 | |
| SCHEMBL30366187 | 0.79 | PARP1 (0.59) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL21614132 | 0.79 | PARP1 (0.59) | PARP1HTR2BHTR2CHTR2AHTR3E | |
| SCHEMBL20986462 | 0.74 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AMAPK1 | |
| SCHEMBL20986460 | 0.74 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AMAPK1 | |
| SCHEMBL20986608 | 0.74 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AMAPK1 | |
| SCHEMBL20986606 | 0.74 | PARP1 (0.49) | PARP1HTR2BHTR2CHTR2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ORION CORPORATION (FI) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | TBXA2R, ADRA2C, ADRB2 | PARP1 1967/4885HTR2B 80/4885HTR2C 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.